P. Hoffmann

发表

Physiological, pharmacological and toxicological considerations of drug‐induced structural cardiac injury

M. Pirmohamed, P. Clements, A. Norris, 2015, British journal of pharmacology.

Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.

P. Hoffmann, Peter Hoffmann, Barbara Warner, 2006, Journal of pharmacological and toxicological methods.

The Challenges of Predicting Drug-Induced QTc Prolongation in Humans

G. Gintant, Jennifer B Pierson, C. Garnett, 2022, Toxicological sciences : an official journal of the Society of Toxicology.

Drug-Induced QTC Prolongation Dangerously Underestimates Proarrhythmic Potential: Lessons From Terfenadine

B. Dumotier, P. Hoffmann, L. Hondeghem, 2011, Journal of cardiovascular pharmacology.

Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs.

Jean-Pierre Valentin, J. Valentin, T. Hammond, 2004, Journal of pharmacological and toxicological methods.

Stroke outcome determination with a prefabricated fibrin-rich macroclot in a thromboembolic rat middle cerebral artery occlusion model

J. Herbert, A. Volk, P. Méric, 1999 .

a New Orally Active Fibrinogen Receptor Antagonist

J. Herbert, J. Maffrand, P. Hoffmann, 2018 .

Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.

J. Herbert, P. Hoffmann, P. Savi, 1998, The Journal of pharmacology and experimental therapeutics.

Translation Strategy for the Qualification of Drug-induced Vascular Injury Biomarkers

N. Arber, G. Vilahur, L. Badimón, 2014, Toxicologic pathology.

The antithrombotic efficacy of the GP IIb/IIIa antagonist SR121787 is potentiated by antithrombin-dependent factor Xa inhibition without an increase in the bleeding risk in the rabbit.

J. Herbert, P. Hoffmann, P. Savi, 1999, Journal of cardiovascular pharmacology.

The synthetic pentasaccharide SR 90107A/org 31540 enhances tissue-type plasminogen activator-induced thrombolysis in rabbits

J. Herbert, P. Hoffmann, A. Bernat, 1996 .

V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs.

J. Herbert, C. Serradeil-Le Gal, P. Hoffmann, 1997, The Journal of pharmacology and experimental therapeutics.

Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide.

J. Herbert, J. Hérault, P. Hoffmann, 1998, Blood.

Antiplatelet and antithrombotic efficacy of SR 121787, a nonpeptide orally active GP IIb/IIIa antagonist, in rabbits: comparison with clopidogrel and aspirin.

J. Herbert, P. Hoffmann, P. Savi, 1997, Journal of cardiovascular pharmacology.

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans.

S. Côté, C. Basson, U. Hassiepen, 2019, Blood.

FXI antibody with a unique binding mode — shows durable effects on markers of anticoagulation in humans Short Title : Novel Factor XI antibody with unique binding mode

Zhiping, Julie, S. Côté, 2019 .

Antagonism of SR 90107A/Org 31540-lnduced Bleeding by Protamine Sulfate in Rats and Mice

J. Herbert, P. Hoffmann, A. Bernat, 1996, Thrombosis and Haemostasis.

The synthetic pentasaccharide SR 90107A/Org 31540 does not release lipase activity into the plasma.

J. Herbert, J. Hérault, P. Hoffmann, 1997, Thrombosis research.

A synthetic heparin/heparan sulfate-like decasaccharide releases lipase activity in vivo. Chemical synthesis and biological activity

J. Herbert, P. Hoffmann, M. Petitou, 1997 .

Peripheral Sympathetic System and Neuropeptide Y Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus Monkeys : Pathomechanistic Role of

Wei Zhou, V. Kaushik, Nick, 2014 .

Osilodrostat (LCI699), a potent 11β-hydroxylase inhibitor, administered in combination with the multireceptor-targeted somatostatin analog pasireotide: A 13-week study in rats.

P. Hoffmann, Tsu-han Lin, H. Schmid, 2015, Toxicology and applied pharmacology.

Structure-based design and pre-clinical characterization of selective and orally bioavailable Factor XIa inhibitors: Demonstrating the power of an integrated S1 protease family approach.

V. Hornak, E. Altmann, A. D'arcy, 2020, Journal of medicinal chemistry.

Interspecies comparison of the antiplatelet, antithrombotic, and hemorrhagic effects of SR 121566A, a novel nonpeptide GP IIb/IIIa antagonist.

J. Herbert, P. Hoffmann, P. Savi, 1999, Journal of cardiovascular pharmacology.

Acute Toxicity of Vildagliptin

P. Hoffmann, P. Bentley, D. Lapadula, 2017, Toxicologic pathology.

Scientific review and recommendations on preclinical cardiovascular safety evaluation of biologics.

Liudmila Polonchuk, Jean-Pierre Valentin, Hugo M Vargas, 2008, Journal of pharmacological and toxicological methods.

SR 121787, a New Orally Active Fibrinogen Receptor Antagonist

J. Herbert, J. Maffrand, P. Hoffmann, 1998, Thrombosis and Haemostasis.

Nonclinical Safety Biomarkers of Drug-induced Vascular Injury

Bradley E. Enerson, I. Mikaelian, P. Hoffmann, 2014, Toxicologic pathology.

Investigation of the Potential of Clozapine to Cause Torsade de Pointes

P. Hoffmann, Barbara Warner, 2002, Adverse drug reactions and toxicological reviews.

Aliskiren toxicity in juvenile rats is determined by ontogenic regulation of intestinal P-glycoprotein expression.

P. Hoffmann, D. Beckman, L. A. McLean, 2014, Toxicology and applied pharmacology.

Integrated and translational nonclinical in vivo cardiovascular risk assessment: gaps and opportunities.

G. Gintant, F. Sellke, S. Pettit, 2013, Regulatory toxicology and pharmacology : RTP.

Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells.

Martin Traebert, B. Dumotier, M. Traebert, 2004, European journal of pharmacology.

The evaluation of drug-induced changes in cardiac inotropy in dogs: Results from a HESI-sponsored consortium.

Eric I. Rossman, Jennifer L. Doyle, Jennifer B Pierson, 2015, Journal of pharmacological and toxicological methods.

Genotoxicity assessment of the antiepileptic drug AMP397, an Ames-positive aromatic nitro compound.

P. Hoffmann, A. Hartmann, Peter Hoffmann, 2002, Mutation research.

Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability

P. Hoffmann, L. Hondeghem, Peter Hoffmann, 2003, Journal of cardiovascular pharmacology.

An evaluation of the utility of LVdP/dt40, QA interval, LVdP/dtmin and Tau as indicators of drug-induced changes in contractility and lusitropy in dogs.

Eric I. Rossman, Jennifer B Pierson, J. Koerner, 2017, Journal of pharmacological and toxicological methods.

Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation

R. Penland, G. Erdemli, C. Springer, 2012, Front. Pharmacol..

Vascular Origin of Vildagliptin-induced Skin Effects in Cynomolgus Monkeys

Serafino Pantano, N. Flavahan, V. Kaushik, 2014, Toxicologic pathology.

The incidence of spontaneous arrhythmias in telemetered beagle dogs, Göttingen Minipigs and Cynomolgus non-human primates: A HESI consortium retrospective analysis.

Matthew M. Abernathy, Eric I. Rossman, Jennifer B Pierson, 2023, Journal of pharmacological and toxicological methods.

Absence of irreversible effects of aliskiren in standard juvenile rat toxicity studies.

P. Hoffmann, D. Beckman, L. A. McLean, 2014, Birth defects research. Part B, Developmental and reproductive toxicology.

Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: a blinded validation.

Martin Traebert, P. Kowey, Donglin Guo, 2012, Heart rhythm.

Drug-Induced QTC Prolongation Dangerously Underestimates Proarrhythmic Potential: Lessons From Terfenadine

B. Dumotier, P. Hoffmann, L. Hondeghem, 2011, Journal of cardiovascular pharmacology.